MX2020004477A - Formulaciones de liberacion prolongada para aplicaciones intra-articulares. - Google Patents

Formulaciones de liberacion prolongada para aplicaciones intra-articulares.

Info

Publication number
MX2020004477A
MX2020004477A MX2020004477A MX2020004477A MX2020004477A MX 2020004477 A MX2020004477 A MX 2020004477A MX 2020004477 A MX2020004477 A MX 2020004477A MX 2020004477 A MX2020004477 A MX 2020004477A MX 2020004477 A MX2020004477 A MX 2020004477A
Authority
MX
Mexico
Prior art keywords
intra
extended release
release formulations
oxabicyclo
dichlorophenyl
Prior art date
Application number
MX2020004477A
Other languages
English (en)
Spanish (es)
Inventor
Carlo Castagnoli
Andreas Fisch
Mathilde Lorscheider
Manjali Laxman Neharkar
Bernd Ulrich Riebesehl
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of MX2020004477A publication Critical patent/MX2020004477A/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4465Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2020004477A 2017-11-10 2018-11-08 Formulaciones de liberacion prolongada para aplicaciones intra-articulares. MX2020004477A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762584589P 2017-11-10 2017-11-10
US201862743864P 2018-10-10 2018-10-10
PCT/IB2018/058788 WO2019092637A1 (en) 2017-11-10 2018-11-08 Extended release formulations for intra-articular applications

Publications (1)

Publication Number Publication Date
MX2020004477A true MX2020004477A (es) 2020-08-03

Family

ID=64402238

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020004477A MX2020004477A (es) 2017-11-10 2018-11-08 Formulaciones de liberacion prolongada para aplicaciones intra-articulares.
MX2023007036A MX2023007036A (es) 2017-11-10 2020-07-13 Formulaciones de liberacion prolongada para aplicaciones intra-articulares.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023007036A MX2023007036A (es) 2017-11-10 2020-07-13 Formulaciones de liberacion prolongada para aplicaciones intra-articulares.

Country Status (23)

Country Link
US (1) US20210177824A1 (enExample)
EP (1) EP3706710B1 (enExample)
JP (1) JP7284750B2 (enExample)
KR (1) KR20200087138A (enExample)
CN (1) CN111278410A (enExample)
AU (1) AU2018364685B2 (enExample)
CA (1) CA3075722A1 (enExample)
CL (1) CL2020001156A1 (enExample)
DK (1) DK3706710T3 (enExample)
ES (1) ES2981903T3 (enExample)
FI (1) FI3706710T3 (enExample)
HR (1) HRP20240808T1 (enExample)
HU (1) HUE066971T2 (enExample)
IL (2) IL274149B2 (enExample)
LT (1) LT3706710T (enExample)
MX (2) MX2020004477A (enExample)
PL (1) PL3706710T3 (enExample)
PT (1) PT3706710T (enExample)
RS (1) RS65659B1 (enExample)
SA (1) SA520411881B1 (enExample)
SI (1) SI3706710T1 (enExample)
TW (2) TWI813597B (enExample)
WO (1) WO2019092637A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3891154B1 (en) * 2018-12-06 2023-08-16 Novartis AG 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
KR20220076371A (ko) * 2020-11-30 2022-06-08 주식회사 엘지화학 캐스파제 저해제를 함유하는 주사용 조성물 및 이의 제조 방법
KR20240133027A (ko) 2023-02-28 2024-09-04 주식회사 포스테라헬스사이언스 올리고펩타이드를 포함하는 서방형 입자 및 이의 제조 방법

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI527590B (zh) * 2011-06-17 2016-04-01 艾瑞斯貿易公司 Fgf-18之凍乾調配物
CA2947031C (en) * 2014-05-13 2023-01-24 Novartis Ag Compounds and compositions for inducing chondrogenesis

Also Published As

Publication number Publication date
SI3706710T1 (sl) 2024-08-30
US20210177824A1 (en) 2021-06-17
LT3706710T (lt) 2024-07-10
JP2021502337A (ja) 2021-01-28
IL305541A (en) 2023-10-01
FI3706710T3 (fi) 2024-07-08
RU2020115439A3 (enExample) 2021-12-10
EP3706710B1 (en) 2024-04-10
RS65659B1 (sr) 2024-07-31
HUE066971T2 (hu) 2024-09-28
EP3706710A1 (en) 2020-09-16
CN111278410A (zh) 2020-06-12
TW201922245A (zh) 2019-06-16
RU2020115439A (ru) 2021-12-10
TW202400164A (zh) 2024-01-01
AU2018364685A1 (en) 2020-03-26
CL2020001156A1 (es) 2020-10-30
PL3706710T3 (pl) 2024-08-05
MX2023007036A (es) 2023-06-28
IL274149B1 (en) 2023-10-01
TWI813597B (zh) 2023-09-01
JP7284750B2 (ja) 2023-05-31
PT3706710T (pt) 2024-06-27
WO2019092637A1 (en) 2019-05-16
IL274149A (en) 2020-06-30
KR20200087138A (ko) 2020-07-20
SA520411881B1 (ar) 2024-01-04
IL274149B2 (en) 2024-02-01
BR112020008806A2 (pt) 2020-10-20
CA3075722A1 (en) 2019-05-16
AU2018364685B2 (en) 2021-05-20
HRP20240808T1 (hr) 2024-09-27
ES2981903T3 (es) 2024-10-14
DK3706710T3 (da) 2024-07-08

Similar Documents

Publication Publication Date Title
EA202092001A1 (ru) Соединения для лечения болезни гентингтона
JOP20220069A1 (ar) عوامل محللة لـ brd9 ثنائية الوظيفة وطرق لاستخدامها
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EP3569601A3 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
ZA202004023B (en) 1,2,4-oxadiazole derivatives as histone deacetylase 6 inhibitors
TN2017000467A1 (en) Amido-substituted cyclohexane derivatives
AR068512A1 (es) Derivados de 4-aril-1h-piridin-2-onas disustituidas, composiciones farmaceuticas que las contienen y usos de las mismas para tratar o prevenir trastornos del sistema nervioso central
MX384800B (es) Derivado de 3-desoxi y composiciones farmaceuticas del mismo.
PE20180601A1 (es) Formulaciones para vacunas contra la neoplasia y metodos para preparar las mismas
HRP20140011T1 (hr) Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja
IL232267A (en) Derivatives of (4-phenylimidazole-2-ram) ethylamine, pharmaceuticals containing them used to treat them in diseases where sodium channel inhibition nav 1.8 is effective
EA201691242A1 (ru) Фармацевтические композиции, содержащие azd9291
JOP20180071B1 (ar) استخدام مشتقات أمينو ألكيل بنزوثيازبين
CL2020001156A1 (es) Formulaciones de liberación prolongada para aplicaciones intra-articulares.
EP4306523A3 (en) Imidazoquinoline compounds and uses thereof
PH12019502150A1 (en) Compounds and methods for the treatment of parasitic diseases
MX373040B (es) Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservador.
JOP20210004A1 (ar) عوامل تحلّل مستقبلات الإستروجين الانتقائية
EA201691490A1 (ru) Фармацевтическая композиция, содержащая бринзоламид
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
MX394624B (es) Inhibidores selectivos hdac6, métodos de preparación y aplicación de los mismos.
BR112015005347A2 (pt) composto, composição farmacêutica, e, método para tratamento ou profilaxia de infecção por hiv ou para tratamento, profilaxia, ou atraso no início de aids
EA201490363A1 (ru) Новые составы на основе (триметоксифениламино)пиримидинилов
ZA202103090B (en) Pharmaceutical formulations of cyclosporine analogs